Recent research from Istanbul has shed light on the intricate relationship between carbonyl stress markers and bipolar disorder (BD), particularly during manic episodes. The study, which was published in the Journal of Affective Disorders, compares the levels of glyoxal (GO), methylglyoxal (MGO), and malondialdehyde (MDA) in male patients with a manic episode of BD who are not on any drugs to those in healthy controls. This study is groundbreaking as it is the first to focus on these specific carbonyl stress markers in BD, examining their changes with treatment.

The study involved 48 male patients hospitalised for manic episodes and 41 healthy male controls. The patient group was carefully selected to exclude individuals with metabolic syndromes, chronic medical conditions, or other psychiatric diagnoses. This careful choice made sure that the changes seen in carbonyl stress markers were more likely to be caused by BD and its treatment and not by other health problems.

Participants underwent blood tests at two stages: upon admission (pre-treatment) and at discharge (post-treatment), after achieving a euthymic state. The levels of GO, MGO, and MDA were measured using high-performance liquid chromatography (HPLC). The study found that while GO levels did not significantly differ between patients and controls, both MGO and MDA levels were notably higher in patients at both stages. Post-treatment, only MDA levels showed a significant decrease, suggesting a direct association with the pathophysiology of BD and the impact of treatment.

The findings indicate that MDA could serve as a potential biomarker for BD, reflecting the illness’s presence and treatment response. MDA, a product of lipid peroxidation, has a longer half-life than other reactive oxygen species, allowing it to inflict prolonged damage to cellular structures and macromolecules. This characteristic may underpin its significant role in BD pathophysiology.

MGO levels, although elevated in BD patients, did not decrease significantly with treatment. This persistence suggests that metabolic factors might have a greater impact on MGO than the psychiatric condition itself. The study also highlighted that BMI and waist circumference were positively correlated with MGO levels, reinforcing the idea that metabolic health significantly impacts carbonyl stress markers.